Boothbay Fund Management’s Rein Therapeutics RNTX Stock Holding History

Boothbay Fund Management’s Portfolio RNTX Stock Details RNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$925K	Buy	+889,450	New	+$1.08M	0.01%	1143
2022 Q3	–	Sell	-13,937	Closed	-$72K	–	2664
2022 Q2	$72K	Hold	13,937	–	–	﹤0.01%	2038
2022 Q1	$143K	Hold	13,937	–	–	﹤0.01%	2009
2021 Q4	$157K	Sell	13,937 -1,679	-11%	-$26K	﹤0.01%	1574
2021 Q3	$319K	Sell	15,616 -4,035	-21%	-$88.4K	0.01%	1302
2021 Q2	$491K	Buy	19,651 +2,070	+12%	+$51.6K	0.02%	1013
2021 Q1	$503K	Buy	+17,581	New	+$602K	0.02%	943

Other funds holding RNTX

Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCM

BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

Boothbay Fund Management's RNTX Position: Q2 2026 in Review

Boothbay Fund Management opened a new position in Rein Therapeutics (RNTX) in Q2 2026: 889,450 shares worth $925K. The stake represents 0.01% of the portfolio and ranks #1143 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in RNTX as recently as Q2 2022.

Boothbay Fund Management first reported a position in RNTX in Q1 2021 and has held it in 7 quarters since. 60 funds tracked by Wall St. Rank hold RNTX as of Q2 2026.

Boothbay Fund Management held 889,450 shares of Rein Therapeutics worth $925K as of Q2 2026.
Rein Therapeutics was a new Boothbay Fund Management position in Q2 2026.
Rein Therapeutics made up 0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #1143 holding.
Boothbay Fund Management first reported a position in Rein Therapeutics in Q1 2021 and has held it in 7 quarters since.
60 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.